Europe
MDxHealth SA, announced its business update and financial results for the year ended December 31, 2018 and provided its strategic outlook for 2019.
Althea Group Holdings Limited is pleased to provide its Half Year Financial Report and Appendix 4D.
Pharma and biotech companies make changes to leadership roles, with new hires at Agios, Notable, Rapamycin, Confo, AVEO and more.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Topping an offer from Billerica, Massachusetts-based company Entegris, Darmstadt, Germany-based Merck KGaA offered an unsolicited $5.9 billion to acquire Versum Materials.
Loos, France-based Genfit announced it is planning an initial public offering (IPO) to raise $100 million. Genfit is a late-stage biopharma company focused on developing therapeutics for metabolic and liver diseases. The area that has the most interest is nonalcoholic steatohepatitis, or NASH.
GENFIT, a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, announces the filing of its 2018 Registration Document with the Autorité des marchés financiers.
GENFIT announced that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its American Depositary Shares, each representing one ordinary share, in the United States, and a concurrent private placement of its ordinary shares in Europe and other countries outside of the United States and Canada.
NOXXON Pharma N.V. announced that it has filed the clinical trial application (CTA) with the Federal Institute for Drugs and Medical Devices, to start a Phase 1/2 clinical trial combining NOX-A12 with radiotherapy to treat newly diagnosed brain cancer patients who would not benefit from the current standard of care and whose tumor cannot be fully resected by surgery.
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful ulcers
PRESS RELEASES